Dimerized T-cell receptor fragment, its compositions and use

Details Dimerized T-cell receptor fragment, its compositions and use Dimerized T-cell receptor fragment, its compositions and use

2011-08-16

2011-08-16

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S327000

Reexamination Certificate

active

07998926

ABSTRACT:
Dimers of a peptide from the T-cell receptor (Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr) (SEQ ID NO:1) are disclosed for preventing the progression to AIDS in an animal model. Methods for delaying the progression to AIDS and restoring normal immunological responses in an animal model following infection are shown and comprise administering through various systemic routes dimeric T-cell receptor peptide Vβ CDR1 to restore normal levels of Th1 cytokines interleukin 2 and interferon-γ, which are suppressed following infection, and those of Th2 derived cytokines interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G, which are stimulated following infection.

REFERENCES:
patent: 5714577 (1998-02-01), Montelaro et al.
patent: 5911990 (1999-06-01), Marchalonis et al.
patent: 5962319 (1999-10-01), Ogawa et al.
patent: 6150337 (2000-11-01), Tam
patent: 7323174 (2008-01-01), Marchalonis et al.
patent: 2002/0028211 (2002-03-01), Kaempfer et al.
patent: 0 109 942 (1984-05-01), None
patent: 0 180 564 (1986-05-01), None
patent: 0 231 039 (1987-08-01), None
patent: 2 189 141 (1987-10-01), None
patent: WO 91/10736 (1991-07-01), None
patent: WO 92/01715 (1992-02-01), None
patent: WO 94/18317 (1994-08-01), None
patent: WO 95/18145 (1995-07-01), None
patent: WO 96/21028 (1996-07-01), None
patent: WO 97/35991 (1997-10-01), None
Liang et al., Cell Immunol. Aug. 25, 1996;172(1):126-34.
Colman et al., Research in Immunology, 1994; 145(1): 33-36.
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Abaza et al. J Protein Chem. Oct. 1992;11(5):445-54.
Janeway et al., Immunobiology, 5th Ed., Garland Science, p. 98 (2001).
The Merck manual of diagnosis and therapy (Mark Beers and Robert Berkow, eds., Published by Merck Research Laboratories, 17th ed., 1999, pp. 2352-2355.
Strom et al., Therapeutic Immunology edited by Austen et al., Blackwell Science, Cambridge, MA, 1996, pp. 451-456.
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bork, 2000, Genome Research 10:398-400.
Skolnick et al., 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Allowed Claims for U.S. Appl. No. 09/591,789, filed Jun. 12, 2000 by Marchalonis et al, 2 pages.
Davis, M.M. et al. (1999). “T-Cell Antigen Receptors,” Chapter 10 inFundamental Immunology, Fourth Edition, Paul W.E. ed., Lippincott-Raven Publishers: Philadelphia, pp. 341-347.
Evavold, B.D. et al. (Dec. 1993). “Ticking the TCR: Selective T-Cell Functions Stimulated by Altered Peptide Ligands,”Immunology Today14(12):602-609. (abstract).
Gait, M.J. et al. (Oct. 1995). “Progress in Anti-HIV Structure-Based Drug Design,”Tibitech13:430-438.
Madrenas, J. et al. (Apr. 1996). “Variant TCR Ligands: New Insights into the Molecular Basis of Antigen-Dependent Signal Transduction and T-Cell Activation,”Seminars in Immunology8(2):83-101. (abstract).
Maggi, E. et al. (Jul. 8, 1994). “Ability of HIV to Promote a TH1 to TH0 Shift and to Replicate Preferentially in TH2 and TH0 Cells,”Science265:244-248.
Marchalonis, J.J. et al. (1994). “Synthetic Autoantigens of Immunoglobulins and T-Cell Receptors: Their Recognition in Aging, Infection, and Autoimmunity,”Society for Experimental Biology and Medicine, pp. 129-147.
Marchalonis, J.J. et al. (2001). “T-Cell Receptor-Derived Peptides in Immunoregulation and Therapy of Retrovirally Induced Immunosuppression,”Critical reviews in Immunology21:57-74.
Öberg, B. et al. (Jul. 1990). “Screening for New Agents,”Eur. J. Clin. Microbiol. Infect Dis.9(7):466-471.
Romagnani, S. et al. (1994). “Tenth Anniversary Perspectives on AIDS : An Alternative View of the Th1/Th2 Switch Hypothesis in HIV Infection,”Aids Research and Human Retroviruses10(5): iii-ix.
Sepulveda, R.T. et al. (Mar. 2003). “T-Cell Receptor Vβ8.1 Peptide reduces Cozsackievirus-Induced Cardiopathology During Murine Acquired Immunodeficiency Syndrome,”Cardiovasc Pharmacol41(3):489-497.
Shearer, G.M. et al. (1992). “T Helper Cell Immune Dysfunction in Asymptomatic HIV-1-Seropositive Individuals: The Role of TH1-TH2 Cross-Regulation,”Chem Immunol54:21-43.
U.S. Appl. No. 09/591,789, filed Jun. 12, 2000, by Marchalonis et al, 41 pages.
Yarchoan, R. et al. (1992). “Correlations Between the in Vitro and in Vivo Activity of Anti-HIV Agents: Implications for Future Drug Development,”J. Enzyme Inhibition6:99-111.
Akuffo, H. et al. (1999). “Natural Killer Cells in Cross-Regulation of IL-12 by IL-10LeishmaniaAntigen-Stimulated Blood Donor Cells,”Clin. Exp. Immunol.117:529-534.
Albright, J.W. et al. (2000). “Soluble Receptors and Other Substances That Regulate Proinflammatory Cytokines in Young and Aging Humans,”J. Gerontol.55A(1):B20-B25.
Aleman, M. et al. (2000). “Interleukin-12 Amplifies theM. lepraehsp65-Cytotoxic Response in the Presence of Tumour Necrosis Factor-α and Interferon-γ Generating CD56+ Effector Cells: Interleukin-4 Downregulates This Effect,”Scand. Immunol.51:262-270.
Boon, T. (1993). “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy,”Int. J. Cancer54:177-180.
Bourdette, D.N. et al. (1994). “Immunity to TCR Peptides in Multiple Sclerosis. 1. Successful Immunization of Patients with Synthetic Vβ 5.2 and Vβ6.1 CDR2 Peptides,”J. Immunol.152:2510-2519.
Bradley, W.G. et al. (1994). “Alteration of in Vivo Cytokine Gene Expression in Mice Infected with a Molecular Clone of the Defective MAIDS Virus,”J. AIDS7:1-9.
Castle, S. et al. (1997). “Evidence of Enhanced Type 2 Immune Response and Impaired Upregulation of a Type 1 Response in Frail Elderly Nursing Home Residents,”Mech. of Ageing&Devel.94:7-16.
Cherwinski, H.M. et al. (1987). “Two Types of Mouse Helper T Cell Clone. III. Further Differences in Lymphokine Synthesis Between Th1 and Th2 Clones Revealed by RNA Hybridization, Functionally Monospecific Bioassays, and Monoclonal Antibodies,”J. Exp. Med.166:1229-1244.
Clerici, M. et al. (1993). “A TH1→TH2 Switch is a Critical Step in the Etiology of HIV Infection,”Immunol. Today14(3):107-110.
De Carli, M. et al. (1994). “Human Th1 and Th2 Cells Functional Properties, Regulation of Development and Role in Autoimmunity,”Autoimmunity18:301-308.
Dehghanpisheh, K. et al. (1995). “Production of IgG Autoantibodies to TCRs in Mice Infected with the Retrovirus LP-BM5,”Intl. Immunol.7(1):31-36.
Dehghanpisheh, K. et al. (1997). “Retrovirally Induced Mouse Anti-TCR Monoclonals Can Synergize the In Vitro Proliferative T Cell Response to Bacterial Superantigens,”Scand. J. Immunol.45:645-654.
Fauci, A.S. (1993). “Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy,”Science262:1011-1018.
Fernández-Gutiérrez, B. et al. (1999). “Early Lymphocyte Activation in Elderly Humans: Impaired T and T-Dependent B Cell Responses,”Exp. Gerontol.34:217-229.
Garcia, V.E. et al. (1999). “IL-18 Promotes Type 1 Cytokine Production From NK Cells and T Cells in Human Intracellular Infection,”J. Immunol.162:6114-6121.
Gazzinelli, R.T. et al. (1992). “Preferential Activation of Th2 Cells During Progression of Retrovirus-Induced Immunodeficiency in Mice,”J. Immunol.148(1):182-188.
Graziosi, C. et al. (1994). “Lack of Evidence for the Dichotomy of TH1 and TH2 Predominance in HIV-Infected Individuals,”Science265:248-252.
Graziosi, C. et al. (1996). “Kinetics of Cytokine Expression During Primary Human Immunodeficiency Virus Type 1 Infection,”Proc. Natl. Acad. S

Affiliated with

Also associated with

Rating

Dimerized T-cell receptor fragment, its compositions and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dimerized T-cell receptor fragment, its compositions and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimerized T-cell receptor fragment, its compositions and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2739644